888-969-2592
Kalkine 0
countryflagCA

Alcon AG

Healthcare US ALC

87.205USD
1.26(1.47%)

Last update at 2025-06-05T16:56:00Z

Day Range

86.6487.61
LowHigh

52 Week Range

80.19100.74
LowHigh

Fundamentals

  • Previous Close 85.94
  • Market Cap44431.36M
  • Volume763777
  • P/E Ratio39.92
  • Dividend Yield0.37%
  • EBITDA2333.00M
  • Revenue TTM9925.00M
  • Revenue Per Share TTM20.06
  • Gross Profit TTM 5516.00M
  • Diluted EPS TTM2.25

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax 1256.00M 832.00M 463.00M 418.00M -635.00000M
Minority interest - - - - -
Net income 1018.00M 974.00M 335.00M 376.00M -531.00000M
Selling general administrative 3250.00M 3209.00M 3068.00M 3057.00M 2694.00M
Selling and marketing expenses - - - - -
Gross profit 5512.00M 5247.00M 4748.00M 4652.00M 2940.00M
Reconciled depreciation 1228.00M 1221.00M 1123.00M 1219.00M 1626.00M
Ebit 1448.00M 1021.00M 616.59M 539.14M -611.36711M
Ebitda 2676.00M 2242.00M 1776.43M 1760.74M 1112.00M
Depreciation and amortization 1228.00M 1221.00M 1159.84M 1221.59M 1723.37M
Non operating income net other - - - - -
Operating income 1413.00M 1039.00M 672.00M 580.00M -482.00000M
Other operating expenses 8498.00M 8416.00M 8045.00M 7711.00M 7315.00M
Interest expense 192.00M 189.00M 134.00M 120.00M 124.00M
Tax provision 238.00M -142.00000M 128.00M 42.00M -104.00000M
Interest income 84.00M 45.00M 16.00M 146.00M 6.00M
Net interest income -120.00000M -155.00000M -146.00000M -162.00000M -131.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 238.00M -142.00000M 128.00M 42.00M -104.00000M
Total revenue 9911.00M 9455.00M 8717.00M 8291.00M 6833.00M
Total operating expenses 4099.00M 4208.00M 4076.00M 4072.00M 3422.00M
Cost of revenue 4399.00M 4208.00M 3969.00M 3639.00M 3893.00M
Total other income expense net -157.00000M -207.00000M -209.00000M -162.00000M -153.00000M
Discontinued operations - - - - -
Net income from continuing ops 1018.00M 974.00M 335.00M 376.00M -531.00000M
Net income applicable to common shares - - 335.00M 376.00M -531.00000M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 30347.00M 29614.00M 29209.00M 27999.00M 27600.00M
Intangible assets 8587.00M 9060.00M 9689.00M 8765.00M 9097.00M
Earning assets - - - - -
Other current assets 129.00M 241.96M 418.00M 95.00M 404.00M
Total liab 8794.00M 8990.00M 9532.00M 8743.00M 8778.00M
Total stockholder equity 21553.00M 20617.02M 19677.00M 19256.00M 18822.00M
Deferred long term liab - - - 557.00M 727.00M
Other current liab 1100.16M 1338.20M 1664.00M 1287.00M 1040.00M
Common stock 20.00M 19.99M 20.00M 20.00M 20.00M
Capital stock 20.00M 20.00M 20.00M 20.00M 20.00M
Retained earnings - - - 19356.00M 18899.00M
Other liab - - 1850.00M 1966.00M 2256.00M
Good will 8946.00M 8926.00M 8970.00M 8905.00M 8905.00M
Other assets - -10.02816M 833.00M 1365.00M 1515.00M
Cash 1829.00M 1094.00M 980.00M 1575.00M 1557.00M
Cash and equivalents - - - - -
Total current liabilities 2278.00M 2479.16M 2782.00M 2472.00M 2258.00M
Current deferred revenue 72.84M -0.83980M 89.00M 108.00M 110.00M
Net debt 3307.00M 4041.00M 4088.00M 2904.00M 2939.00M
Short term debt 169.00M 216.00M 168.00M 174.00M 232.00M
Short long term debt 101.00M 135.00M 97.00M 107.00M 162.00M
Short long term debt total 5136.00M 5135.00M 5068.00M 4479.00M 4496.00M
Other stockholder equity - - 19657.00M 19236.00M 18802.00M
Property plant equipment - - 4416.00M 4083.00M 3783.00M
Total current assets 6309.00M 5647.00M 5193.00M 5386.00M 4987.00M
Long term investments 751.00M 319.00M 108.00M 52.00M 40.00M
Net tangible assets - - 1018.00M 2143.00M 1547.00M
Short term investments 1.00M 7.00M -179.00000M 3.00M 12.00M
Net receivables 2082.00M 1981.33M 1686.00M 1814.00M 1382.00M
Long term debt 4538.00M 4594.00M 4541.00M 3966.00M 3949.00M
Inventory 2268.00M 2322.00M 2109.00M 1899.00M 1644.00M
Accounts payable 773.00M 811.00M 861.00M 903.00M 876.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 21533.00M 20597.02M 19657.00M 19236.00M 18802.00M
Additional paid in capital - - - - -
Common stock total equity - - - - 20.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 495.00M 496.15M 243.00M 399.00M 211.00M
Deferred long term asset charges - - - - -
Non current assets total 24038.00M 23967.00M 24016.00M 22613.00M 22613.00M
Capital lease obligations 497.00M 406.00M 430.00M 406.00M 385.00M
Long term debt total - - - 4305.00M 4264.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1865.00000M -18.00000M -572.00000M -1011.00000M -1001.00000M
Change to liabilities -48.00000M 60.00M -21.00000M 84.00M 44.00M
Total cashflows from investing activities -1865.00000M -1198.00000M -572.00000M -1011.00000M -1001.00000M
Net borrowings 208.00M -63.00000M 536.00M 3293.00M 15.00M
Total cash from financing activities -8.00000M -123.00000M 466.00M 659.00M -78.00000M
Change to operating activities -192.00000M 88.00M -23.00000M 8.00M 66.00M
Net income 335.00M 376.00M -531.00000M -656.00000M -227.00000M
Change in cash -595.00000M 18.00M 735.00M 595.00M 55.00M
Begin period cash flow 1575.00M 1557.00M 822.00M 227.00M 172.00M
End period cash flow 980.00M 1575.00M 1557.00M 822.00M 227.00M
Total cash from operating activities 1217.00M 1345.00M 823.00M 920.00M 1140.00M
Issuance of capital stock - - - - -
Depreciation 1123.00M 1219.00M 1626.00M 1425.00M 1638.00M
Other cashflows from investing activities - -18.00000M -5.00000M -1.00000M -1.00000M
Dividends paid -100.00000M -54.00000M 54.00M 54.00M 54.00M
Change to inventory -217.00000M -326.00000M -159.00000M -108.00000M -150.00000M
Change to account receivables -164.00000M -198.00000M 43.00M -115.00000M 53.00M
Sale purchase of stock - - - - -
Other cashflows from financing activities 2428.00M 3.00M 535.00M 2720.00M -78.00000M
Change to netincome 380.00M 128.00M -101.00000M 290.00M -284.00000M
Capital expenditures 745.00M 1180.00M 567.00M 676.00M 712.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -527.00000M -314.00000M -45.00000M -48.00000M 80.00M
Stock based compensation 140.00M 138.00M 105.00M 83.00M -234.00000M
Other non cash items 18.00M -116.00000M -228.00000M -208.00000M -44.00000M
Free cash flow 472.00M 165.00M 256.00M 244.00M 428.00M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALC
Alcon AG		 1.26 1.47% 87.20 39.92 28.41 4.48 2.02 4.85 31.45
ISRG
Intuitive Surgical Inc		 2.21 0.40% 560.16 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA		 0.60 0.43% 140.17 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme		 0.45 0.16% 278.16 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company		 1.05 0.61% 171.99 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

View All

Profile

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Alcon AG

Chemin de Blandonnet 8, Geneva, Switzerland, 1214

Key Executives

Name Title Year Born
Mr. F. Michael Ball Exec. Chairman 1955
Mr. David J. Endicott CEO & Director 1965
Mr. Arthur B. Cummings M.D. Exec. Director 1962
Mr. Timothy C. Stonesifer Chief Financial Officer 1967
Margaret Buckley Chief Accounting Officer NA
Dr. Franck Leveiller Sr. VP, Head of Global R&D and Chief Scientific Officer NA
Ms. Sue-Jean Lin Sr. VP & Chief Information and Transformation Officer 1969
Mr. Royce R. Bedward Sr. VP, Gen. Counsel & Corp. Sec. 1966
Mr. Laurent Attias Head of Corp. Devel., Strategy, BD&L and M&A 1968
Ms. Kimberly Martin Sr. VP & Chief HR Officer 1975

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.